Our mission: transforming the patient’s experience with our passion, know-how and dedication..
Partner Stories


AOP Health and RHEACELL have formed a strategic partnership to deliver breakthrough therapies for the "butterfly children's" disease Epidermolysis bullosa (EB) and chronic venous ulcers. This partnership aims to provide patients with high unmet medical needs access to innovative cell therapies.
Read more here: RHEACELL and AOP Health: Strategic Partnership


Our mission is to provide patients with rare diseases access to urgently needed therapeutic innovation. This partnership with stem cell pioneer RHEACELL enables us to jointly bring new treatment options to patients living with chronic venous wounds or Epidermolysis bullosa, who currently have limited or no treatment options. Our teams are fully committed to making these groundbreaking treatments available to all patients affected.


From the earliest stages of asset evaluation through to contracting, the professional chemistry between the AOP Health and RHEACELL teams was evident. With a shared mindset and mutual commitment, we’ve built a strong foundation — and we’re truly looking forward to shaping the future together.


This partnership marks a significant milestone for RHEACELL and the further development of our stem cell medication programs. Collaborating with an established partner like AOP Health to commercialize our stromal cell medications will allow us to bring our innovative therapies to the European patients faster and more efficiently.


This alliance came together because of shared values, trust, and a deep belief in what science can achieve. By joining forces with RHEACELL, we are strengthening our innovation pipeline and giving AOP Health an additional growth engine—one that supports our expansion into new therapeutic areas and markets.